文献速递类风湿关节炎

难治性类风湿关节炎中改善病情抗风湿药疗效不佳的机制:基于系统文献检索的叙述性综述

Mechanisms underlying DMARD inefficacy in difficult-to-treat rheumatoid arthritis: a narrative review with systematic literature search.
PubMed 文献 · Rheumatology (Oxford) · 2022-01-01

本叙述性综述基于系统文献检索,概述难治性类风湿关节炎(D2T RA)患者对生物制剂和/或靶向合成改善病情抗风湿药(DMARDs)应答不佳的潜在(免疫)机制,讨论基因表达水平差异和临床特征的影响。确切机制仍 largely 未知,但患者间异质性支持 D2T RA 是涉及不同致病机制的综合征这一假设。

要点

  • D2T RA 患者对生物制剂和/或靶向合成 DMARDs 失败后仍有症状,多种因素可促成。
  • 促成因素包括治疗不依从、合并症和共存模拟疾病(如纤维肌痛)。
  • 现有生物制剂和/或靶向合成 DMARDs 可能真正无效(「真性」难治性 RA)和/或导致不可接受的副作用。

核心结论

  • 确切潜在机制仍 largely 未知,但患者间异质性支持 D2T RA 是涉及不同致病机制的综合征这一假设。

研究设计与样本

  • 本研究为基于系统文献检索的叙述性综述。

主要发现

  • 多种因素可促成 D2T RA,包括治疗不依从、合并症和共存模拟疾病(如纤维肌痛)。
  • 现有生物制剂和/或靶向合成 DMARDs 可能真正无效(「真性」难治性 RA)和/或导致不可接受的副作用。
  • 综述讨论了不同基因表达水平和临床特征的影响。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Management of RA patients has significantly improved over the past decades. However, a substantial proportion of patients is difficult-to-treat (D2T), remaining symptomatic after failing biological and/or targeted synthetic DMARDs. Multiple factors can contribute to D2T RA, including treatment non-adherence, comorbidities and co-existing mimicking diseases (e.g. fibromyalgia). Additionally, currently available biological and/or targeted synthetic DMARDs may be truly ineffective ('true' refractory RA) and/or lead to unacceptable side effects. In this narrative review based on a systematic literature search, an overview of underlying (immune) mechanisms is presented. Potential scenarios are discussed including the influence of different levels of gene expression and clinical characteristics. Although the exact underlying mechanisms remain largely unknown, the heterogeneity between individual patients supports the assumption that D2T RA is a syndrome involving different pathogenic mechanisms.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Roodenrijs NMT, Welsing PMJ, van Roon J, et al. Mechanisms underlying DMARD inefficacy in difficult-to-treat rheumatoid arthritis: a narrative review with systematic literature search. Rheumatology (Oxford). 2022. PMID: 35238332. doi:10.1093/rheumatology/keac114

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。